Year: 2020
Type: article
Abstract: Repetitive transcranial magnetic stimulation (rTMS) is implemented to treat many clinical diagnoses.The most common clinical patients receiving rTMS are those suffering from treatment resistant depression (TRD).As a treatment for TRD, rTMS is thought to modulate circuits dysregulated by the disease (Fox et al., 2012).Considering many clinical populations have overlapping dysregulated circuits (Goodkind et al., 2015; McTeague et al., 2017), rTMS holds tremendous potential to treat myriad diseases.One such disease that is manifest by dysregulated circuits is substance use disorder (SUD) (Volkow et al., 2016).The dysregulation spawns from the mesocorticolimbic dopamine (MCL-DA) system and linked to initiation and maintenance of addictive behaviors (Goldstein and Volkow, 2002).Drug use increases DA release in MCL-DA system (Jay, 2003; Kelley, 2004;Nestler, 2005), which is thought to be an important element in learning, goal-directed behavior, and reward processing (Everitt and Robbins, 2005; Kalivas and O'Brien, 2008).The MCL-DA system was modulated with repeated drug exposures to increase dysregulations in SUDs.Cortical rTMS modulates dopamine release in the MCL-DA (Strafella et al., 2001;Strafella, 2003) suggesting rTMS has therapeutic potential for clinical disorders related to DA, such as SUDs.
Source: Frontiers in Neuroscience
Author: Vaughn R. Steele
Institution: Yale University
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,950
Funder: National Institute on Drug Abuse
OpenAlex ID: W3094180652